Molecular Neurotrauma and Haemostasis Unit
The blood-brain barrier (BBB) becomes compromised in traumatic brain injury (TBI) and ischemic stroke patients, particularly after treatment with the thrombolytic agent tissue-type plasminogen activator (t-PA).
We identified an essential signalling event within key cells of the BBB that are triggered by t-PA and are important in the control of BBB permeability. Moreover, blockade of this signalling pathway attenuated the capacity of the tPA to open the BBB.
We are now evaluating the potential beneficial effects of this approach in mouse models of ischemic stroke and in TBI.
Molecular Neurotrauma and Haemostasis Unit
Find out more about the Molecular Neurotrauma and Haemostasis Unit
Find out moreOur partners
News & articles
from Alfred Health
